<DOC>
	<DOCNO>NCT01271959</DOCNO>
	<brief_summary>The purpose research study collect information patient 's medical record test call ChemoFx® order understand doctor may use result ChemoFx® treat patient cancer .</brief_summary>
	<brief_title>A Study ChemoFx® Chemoresponse Assay Solid Tumors - ChemoFx® Registry Study</brief_title>
	<detailed_description>While study support clinical use ChemoFx® cancer patient , additional data need assess utilization product clinical practice . Such post-market data information could employ product improvement well development standard regulation . This multicenter registry study 3,000 patient solid tumor . The study randomize , interventional treat physician free choose employ ChemoFx® result clinical management individual patient . Sites select Precision 's clinical trial team base past commercial usage ChemoFx® . Subjects may enrol study diagnose solid tumor malignancy ChemoFx® order . ChemoFx® order normal commercial process therefore bill patient 's medical insurance . All subject appropriately consent study-specific data collect . A limited dataset patient demographic , oncology history , therapeutic intervention collect addition ChemoFx® assay usage . Subjects treat base medical judgment treat physician ( ) . Patient survival data collect five year follow ChemoFx® commercial order . Additional disease progression data may collect Precision 's CRAs participate site . Optional Cell Research Informed consent obtain document subject 's consent use excess cell remain Precisions ' commercial laboratory additional research . This portion study may involve DNA , RNA , proteomic research . To ensure anonymity subject , identifier would link sample subject remove . The sample would gene expression profile quantitative protein expression analysis perform . The goal research would identify set informative gene , intermediary , protein develop predictive algorithm ( ) seek link expression level gene , gene signature , intermediary , protein clinical outcome patient . This portion study require additional subject procedure . Neither physicians patient receive result research perform . Results place subject health care record affect medical care .</detailed_description>
	<criteria>Pathologically confirm diagnosis solid tumor malignancy ; Medically indicate receive chemotherapy ; Fresh tissue submit solid tumor malignancy test ChemoFx® assay August , 2006 ; Final ChemoFx® assay report available ; Subject must least 18 year age ; Subject must sign date IRB approve ICF . Enrolled PT103 , PT106 , PT206 , PT301 , PT304 ; Pregnant lactate subject ; Subjects indicate receive chemotherapy disease ; Subjects psychiatric addictive disorder would preclude obtain informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>Fallopian Tube</keyword>
	<keyword>Peritoneal</keyword>
	<keyword>Uterine Neoplasms</keyword>
	<keyword>Vulva</keyword>
	<keyword>Endometrial</keyword>
	<keyword>Cervical</keyword>
	<keyword>Lung</keyword>
	<keyword>Carcinoid</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Breast</keyword>
	<keyword>Assay</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Refractory</keyword>
	<keyword>Persistent</keyword>
	<keyword>Chemoresponse</keyword>
</DOC>